Market Closed -
Euronext Amsterdam
16:35:27 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
0.8
EUR
|
-2.44%
|
|
+76.60%
|
-90.17%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
21.01
|
108.7
|
180
|
380.4
|
248.8
|
20.85
|
20.85
|
-
|
Enterprise Value (EV)
1 |
21.01
|
108.7
|
154
|
365.7
|
218.6
|
193.7
|
1.303
|
14.15
|
P/E ratio
|
-2.72
x
|
-8.77
x
|
-10.9
x
|
-30.2
x
|
-8.06
x
|
-7.27
x
|
-1.12
x
|
0.97
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
35.3
x
|
-
|
-58,614
x
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
34
x
|
-
|
-53,497
x
|
-
|
-
|
EV / EBITDA
|
-2.74
x
|
-
|
-9.71
x
|
-29
x
|
-7.55
x
|
-6.75
x
|
-0.08
x
|
-0.92
x
|
EV / FCF
|
-
|
-
|
-
|
-32.4
x
|
-10
x
|
-17.6
x
|
-0.1
x
|
-1.03
x
|
FCF Yield
|
-
|
-
|
-
|
-3.09%
|
-9.96%
|
-5.69%
|
-1,051%
|
-97.5%
|
Price to Book
|
-
|
-
|
-
|
-
|
8.57
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
8,208
|
19,975
|
19,975
|
20,020
|
24,105
|
26,067
|
26,067
|
-
|
Reference price
2 |
2.560
|
5.440
|
9.010
|
19.00
|
10.32
|
0.8000
|
0.8000
|
0.8000
|
Announcement Date
|
28/03/19
|
26/03/20
|
30/04/21
|
28/04/22
|
19/04/23
|
24/04/24
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
-
|
-
|
10.76
|
-
|
-0.00362
|
-
|
-
|
EBITDA
1 |
-7.675
|
-
|
-15.86
|
-12.63
|
-28.95
|
-28.67
|
-16.4
|
-15.4
|
EBIT
1 |
-
|
-
|
-16.01
|
-12.8
|
-29.11
|
-28.84
|
-18.47
|
31.97
|
Operating Margin
|
-
|
-
|
-
|
-118.9%
|
-
|
796,602.21%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-16.51
|
-12.22
|
-28.36
|
-28.58
|
-18.7
|
31.8
|
Net income
1 |
-7.737
|
-7.823
|
-16.51
|
-12.66
|
-28.16
|
-28.34
|
-18.7
|
19.13
|
Net margin
|
-
|
-
|
-
|
-117.57%
|
-
|
782,928.18%
|
-
|
-
|
EPS
2 |
-0.9400
|
-0.6200
|
-0.8300
|
-0.6300
|
-1.280
|
-1.120
|
-0.7167
|
0.8267
|
Free Cash Flow
1 |
-
|
-
|
-
|
-11.28
|
-21.78
|
-11.03
|
-13.7
|
-13.8
|
FCF margin
|
-
|
-
|
-
|
-104.84%
|
-
|
304,613.26%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/03/19
|
26/03/20
|
30/04/21
|
28/04/22
|
19/04/23
|
24/04/24
|
-
|
-
|
Fiscal Period: December |
2019 S1
|
2023 S1
|
2023 S2
|
---|
Net sales
1 |
-
|
-
|
-0.00362
|
EBITDA
|
-
|
-
|
-
|
EBIT
1 |
-3.077
|
-
|
-18.14
|
Operating Margin
|
-
|
-
|
501,243.09%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-17.82
|
Net income
1 |
-
|
-10.72
|
-17.63
|
Net margin
|
-
|
-
|
486,906.08%
|
EPS
2 |
-
|
-0.4400
|
-0.6800
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
30/07/19
|
07/09/23
|
24/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
26
|
14.7
|
30.1
|
18.5
|
19.6
|
6.7
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-11.3
|
-21.8
|
-11
|
-13.7
|
-13.8
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-59.2%
|
-131%
|
-107%
|
-68.1%
|
-216%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
1.200
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.02
|
-
|
0.06
|
0.02
|
0.01
|
0.01
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
0.19%
|
-
|
-386.74%
|
-
|
-
|
Announcement Date
|
28/03/19
|
26/03/20
|
30/04/21
|
28/04/22
|
19/04/23
|
24/04/24
|
-
|
-
|
Average target price
41.57
EUR Spread / Average Target +5,095.83% Consensus |
1st Jan change
|
Capi.
|
---|
| -90.17% | 22.26M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|